ChemoCentryx Inc.

Mountain View Acres, CA, United States

ChemoCentryx Inc.

Mountain View Acres, CA, United States
SEARCH FILTERS
Time filter
Source Type

Patent
ChemoCentryx Inc. | Date: 2017-01-18

Oxindole compounds useful for the treatment of CCR(9) mediated conditions or diseases are provided.


Patent
ChemoCentryx Inc. | Date: 2017-01-12

Methods of treating a human suffering from or susceptible to C3 glomerulopathy comprising administering to the human an effective amount of a C5aR antagonist are provided.


Patent
ChemoCentryx Inc. | Date: 2017-08-09

Intermediates and methods are provided for the preparation of selected C5aR antagonist compounds.


Patent
ChemoCentryx Inc. | Date: 2016-11-17

Compounds are provided as inhibitors of CXCR2, having the structure:


Patent
ChemoCentryx Inc. | Date: 2016-11-17

Compounds are provided as chemokine inhibitors having the structure:


Patent
ChemoCentryx Inc. | Date: 2016-11-17

Compounds are provided that are modulators of the C5a receptor. The compounds are substituted piperidines and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activtation of C5a receptors.


Patent
ChemoCentryx Inc. | Date: 2016-12-19

Compounds are provided that act as potent antagonists of the CCR2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as controls in assays for the identification of CCR2 antagonists.


Patent
ChemoCentryx Inc. | Date: 2017-01-06

Compounds are provided that are modulators of the C5a receptor. The compounds are substituted piperidines and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activation of C5a receptors.


Compounds are provided that act as potent antagonists of the CCR2 receptor. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases and as controls in assays for the identification of CCR2 antagonists.


Patent
ChemoCentryx Inc. | Date: 2016-03-18

Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are diazole lactam derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated disease, and as controls in assays for the identification of competitive CCR1 antagonists.

Loading ChemoCentryx Inc. collaborators
Loading ChemoCentryx Inc. collaborators